Literature DB >> 18200329

Comparative efficacy of pilocarpine, timolol and latanoprost in experimental models of glaucoma.

S K Gupta1, R Agarwal, N D Galpalli, S Srivastava, S S Agrawal, R Saxena.   

Abstract

Intraocular pressure (IOP)-lowering effects of investigational antiglaucoma drugs often need comparison with existing drugs, but detailed data showing comparative efficacy of antiglaucoma drugs with different mechanism of action has not been reported so far. This study was designed to establish baseline information of the IOP-lowering effect of three currently used antiglaucoma drugs in three experimental models in rabbits, so that they act as a benchmark for the efficacy evaluation of the future experimental antiglaucoma drugs. The IOP-lowering effect of single-drop application of pilocarpine, timolol and latanoprost was studied in normotensive, water loading and steroid-induced models of glaucoma in rabbits. The noncontact tonometer was used for the first time to estimate IOP in rabbits. The peak IOP-lowering effect of pilocarpine, timolol and latanoprost in normotensive rabbit eye was 18.23%, 20% and 22.56%, respectively. In water-loading model, the maximum protection against the rise in IOP was shown by latanoprost (40.27%), followed by timolol (31.39%) and pilocarpine (28.91%). In steroid-pretreated rabbit eyes, peak IOP-lowering effects of pilocarpine, timolol and latanoprost were 25.65%, 34.21% and 35.06%, respectively. Therefore, the latanoprost was found to be most effective in all three models followed by timolol and pilocarpine. The results of this study can be used for future preclinical investigations for the assessment of IOP-lowering activity of potential antiglaucoma drugs.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18200329     DOI: 10.1358/mf.2007.29.10.1147765

Source DB:  PubMed          Journal:  Methods Find Exp Clin Pharmacol        ISSN: 0379-0355


  11 in total

1.  In vitro and in vivo efficacy of SYL040012, a novel siRNA compound for treatment of glaucoma.

Authors:  Tamara Martínez; Maria Victoria González; Ingo Roehl; Natalia Wright; Covadonga Pañeda; Ana Isabel Jiménez
Journal:  Mol Ther       Date:  2013-09-12       Impact factor: 11.454

2.  Phase I clinical trial of SYL040012, a small interfering RNA targeting β-adrenergic receptor 2, for lowering intraocular pressure.

Authors:  Javier Moreno-Montañés; Belén Sádaba; Verónica Ruz; Almudena Gómez-Guiu; Javier Zarranz; María Victoria González; Covadonga Pañeda; Ana Isabel Jimenez
Journal:  Mol Ther       Date:  2013-09-12       Impact factor: 11.454

3.  Design and evaluation of novel fast forming pilocarpine-loaded ocular hydrogels for sustained pharmacological response.

Authors:  SivaNaga S Anumolu; Yashveer Singh; Dayuan Gao; Stanley Stein; Patrick J Sinko
Journal:  J Control Release       Date:  2009-03-31       Impact factor: 9.776

4.  Effect of tetracaine on intraocular pressure in normal and hypertensive rabbit eyes.

Authors:  Ali Asghar Sarchahi; Hooman Bozorgi
Journal:  J Ophthalmic Vis Res       Date:  2012-01

5.  Latanoprost ophthalmic solution in the treatment of open angle glaucoma or raised intraocular pressure: a review.

Authors:  Andrea Russo; Ivano Riva; Teodoro Pizzolante; Federico Noto; Luciano Quaranta
Journal:  Clin Ophthalmol       Date:  2008-12

6.  Ocular hypotensive effects of a Rho-associated protein kinase inhibitor in rabbits.

Authors:  Muhammad Irfan Kamaruddin; Momoko Nakamura-Shibasaki; Yu Mizuno; Yoshiaki Kiuchi
Journal:  Clin Ophthalmol       Date:  2017-03-31

7.  Surface engineering of macrophages with nanoparticles to generate a cell-nanoparticle hybrid vehicle for hypoxia-targeted drug delivery.

Authors:  Christopher A Holden; Quan Yuan; W Andrew Yeudall; Deborah A Lebman; Hu Yang
Journal:  Int J Nanomedicine       Date:  2010-02-02

Review 8.  An emerging treatment option for glaucoma: Rho kinase inhibitors.

Authors:  Sean K Wang; Robert T Chang
Journal:  Clin Ophthalmol       Date:  2014-05-09

9.  Effect of potassium channel openers in acute and chronic models of glaucoma.

Authors:  Shital S Panchal; Anita A Mehta; Devdas D Santani
Journal:  Taiwan J Ophthalmol       Date:  2016-06-20

10.  Stable Gastric Pentadecapeptide BPC 157 Therapy of Rat Glaucoma.

Authors:  Tamara Kralj; Antonio Kokot; Mirna Zlatar; Sanja Masnec; Katarina Kasnik Kovac; Marija Milkovic Perisa; Lovorka Batelja Vuletic; Ana Giljanovic; Sanja Strbe; Suncana Sikiric; Slaven Balog; Bojan Sontacchi; Dijana Sontacchi; Matko Buljan; Eva Lovric; Alenka Boban Blagaic; Anita Skrtic; Sven Seiwerth; Predrag Sikiric
Journal:  Biomedicines       Date:  2021-12-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.